New PD-1 Inhibitor Approved for Esophageal Cancer
(MedPage Today) -- The FDA approved tislelizumab (Tevimbra) for advanced/metastatic esophageal squamous cell carcinoma (ESCC) previously treated with chemotherapy, BeiGene announced. The approval stipulates use of the PD-1 inhibitor in adults... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 15, 2024 Category: American Health Source Type: news

FDA Approves New Esophageal Cancer Drug FDA Approves New Esophageal Cancer Drug
The checkpoint inhibitor is approved for second-line treatment of patients with esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-L1 inhibitor.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 15, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

FDA Approves Tevimbra (tislelizumab-jsgr) for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
BASEL, Switzerland& BEIJING& CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 14, 2024 Category: Drugs & Pharmacology Source Type: news

Beta-defensin index: A functional biomarker for oral cancer detection
 Cell Reports Mediine AccessPublished:March 04, 2024DOI:https://doi.org/10.1016/j.xcrm.2024.101447SummaryThere is an unmet clinical need for a non-invasive and cost-effective test for oral squamous cell carcinoma (OSCC) that informs clinicians when a biopsy is warranted. Human beta-defensin 3 (hBD-3), an epithelial cell-derived anti-microbial peptide, is pro-tumorigenic and overexpressed in early-stage OSCC compared to hBD-2. We validate this expression dichotomy in carcinoma in situ and OSCC lesions using immunofluorescence microscopy and flow cytometry. The proportion of hBD-3/hBD-2 levels in non-invasivel...
Source: Dental Technology Blog - March 12, 2024 Category: Dentistry Source Type: news

Neoadjuvant Chemo Adds Significant Treatment Benefit in Penile Cancer
THURSDAY, March 7, 2024 -- Neoadjuvant chemotherapy (NAC) with lymphadenectomy for locally advanced penile squamous cell carcinoma (PSCC) is well tolerated and improves outcomes, according to a study published online Feb. 16 in the Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 7, 2024 Category: Pharmaceuticals Source Type: news

Ask Dr Rosemary Leonard: Why won't my GP monitor my skin cancer?
A reader wonders if their GP is right not to want to carry out further checks after a raised lump was found to be squamous cell cancer (Source: Daily Express - Health)
Source: Daily Express - Health - March 5, 2024 Category: Consumer Health News Source Type: news

Novel Therapy Promising for Radiation-Induced Oral Mucositis
(MedPage Today) -- The first-in-class uridine phosphorylase inhibitor TK-90 almost completely eliminated severe oral mucositis (SOM) in patients with non-metastatic squamous cell carcinoma of the head and neck who underwent radiation therapy, a... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 5, 2024 Category: Hematology Source Type: news

Gene-Guided Immunotherapy Misses Mark in Recurrent/Metastatic Head and Neck Cancer
(MedPage Today) -- Gene-guided treatment selection for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) failed to improve disease control versus random treatment selection in a small preliminary clinical trial. Personalized treatment... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 4, 2024 Category: Hematology Source Type: news

Two Pembrolizumab Trials in Head and Neck Cancer Yield Divergent Results
(MedPage Today) -- Two first-line trials involving pembrolizumab (Keytruda)-based combinations for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) delivered mixed results. While first-line pembrolizumab plus... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 1, 2024 Category: Hematology Source Type: news

Inadequate Knowledge: HPV and Oropharyngeal Carcinoma Inadequate Knowledge: HPV and Oropharyngeal Carcinoma
Dr Maurie Markman discusses a recent paper investigating knowledge about the relationship between HPV and oropharyngeal squamous cell carcinoma.Medscape Oncology (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - February 29, 2024 Category: Infectious Diseases Tags: Hematology-Oncology Commentary Source Type: news

Do we recognize oral cancer? Primary professional delay in diagnosis of oral squamous cell carcinoma
ConclusionsOSCC patients seek care actively. Primary professional delay affects the care of every tenth OSCC patient.Clinical relevanceThe role of health care professionals is essential for early OSCC diagnosis, especially in urgent care. Clinicians ’ knowledge of the typical symptoms and findings of OSCC should be improved. (Source: Dental Technology Blog)
Source: Dental Technology Blog - February 14, 2024 Category: Dentistry Source Type: news

Why Is HOOKIPA Pharma Stock Trading Lower Today?
HOOKIPA Pharma Inc HOOK will focus its resources on prioritizing the clinical development of a randomized trial for its HB-200 program in human papillomavirus 16 positive (HPV16+) head and neck squamous cell carcinoma (HNSCC) and its two Gilead Science Inc GILD-partnered infectious disease cure…#hookipapharmainchook #gileadscienceinc #hookipa #rocheholdingsag #rhhby #kras #gileadsciences #gilead (Source: Reuters: Health)
Source: Reuters: Health - January 29, 2024 Category: Consumer Health News Source Type: news

Adding Immunotherapy, Anti-TIGIT in First Line Boosts OS in Esophageal Cancer
(MedPage Today) -- SAN FRANCISCO -- Adding the novel anti-TIGIT monoclonal antibody tiragolumab plus atezolizumab (Tecentriq) to standard first-line chemotherapy significantly improved survival for patients with advanced esophageal squamous cell... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 20, 2024 Category: Gastroenterology Source Type: news

Community Cancer Centers Treating More HPV-Related Head, Neck Cancer
THURSDAY, Jan. 11, 2024 -- Treatment of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma has recently shifted to community cancer centers, with an increase in the proportion of nonsurgical treatment and worse overall... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 11, 2024 Category: Pharmaceuticals Source Type: news